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In recent years, increasing evidence has emerged demonstrating that high-dose ascor-
bate bears cytotoxic effects on cancer cells in vitro and in vivo, making ascorbate a
pro-oxidative drug that catalyzes hydrogen peroxide production in tissues instead of acting
as a radical scavenger.This anticancer effect of ascorbate is hypoxia-inducible factor-1α- and
O2-dependent. However, whether the intracellular mechanisms governing this effect are
modulated by epigenetic phenomena remains unknown. We treated human melanoma
cells with physiological (200µM) or pharmacological (8 mM) ascorbate for 1 h to record
the impact on DNA methyltransferase (DNMT)-activity, histone deacetylases (HDACs), and
microRNA (miRNA) expression after 12 h. The results were analyzed with the MIRUMIR
online tool that estimates the power of miRNA to serve as potential biomarkers to pre-
dict survival of cancer patients. FACS cell-cycle analyses showed that 8 mM ascorbate
shifted BLM melanoma cells toward the sub-G1 fraction starting at 12 h after an initial pri-
mary G2/M arrest, indicative for secondary apoptosis induction. In pharmacological doses,
ascorbate inhibited the DNMT activity in nuclear extracts of MeWo and BLM melanoma
cells, but did not inhibit human HDAC enzymes of classes I, II, and IV. The expression of
151 miRNAs was altered 12 h after ascorbate treatment of BLM cells in physiological or
pharmacological doses. Pharmacological doses up-regulated 32 miRNAs (≥4-fold) mainly
involved in tumor suppression and drug resistance in our preliminary miRNA screening
array.The most prominently up-regulated miRNAs correlated with a significantly increased
overall survival of breast cancer or nasopharyngeal carcinoma patients of the MIRUMIR
database with high expression of the respective miRNA. Our results suggest a possible
epigenetic signature of pharmacological doses of ascorbate in human melanoma cells and
support further pre-clinical and possibly even clinical evaluation of ascorbate for melanoma
therapy.
Keywords: ascorbate, vitamin C, cancer, melanoma, epigenetics, microRNA, HDAC, DNMT
INTRODUCTION
In recent years, a large number of studies demonstrated that
in pharmacological doses, ascorbic acid (ascorbate, vitamin C)
in the low micromolar-range exerts cytotoxic effects on can-
cer cells in vitro and in vivo (1–3) via pro-oxidative mech-
anisms (4). This cytotoxicity is conducted by ascorbyl rad-
icals and H2O2 being catalyzed by serum components (5).
Hypoxic conditions and hypoxia-inducible factor-1α (HIF-1α)-
signaling, both present in cancer metastases, confer resistance
to the cancer cells toward ascorbate-induced cytotoxicity (5),
while ascorbate inhibits HIF-1 with mechanisms of iron com-
petition (6). This bears a strong clinical implication, since
Abbreviations: DNMT, DNA methyltransferase; DNMTi, DNA methyltransferase
inhibitor; HDAC, histone deacetylase; HDACi, histone deacetylase inhibitor; i.v.,
intravenous; miRNA, microRNA; ROS, reactive oxygen species; SAHA, suberoy-
lanilide hydroxamic acid; TSA, trichostatin A.
increased tumor ascorbate is associated with extended disease-
free survival and decreased HIF-1 activation in human col-
orectal cancer (7). Likewise, low ascorbate levels are associ-
ated with increased HIF-1 activity and an aggressive tumor
phenotype in endometrial cancer (8). Interestingly, ascorbate
has a preferential toxicity toward melanoma cells (9). In B16,
melanoma-bearing mice spontaneous lung metastasis is inhib-
ited by sodium ascorbate supplementation in drinking water in
mice fed a restricted diet (low in tyrosine and phenylalanine)
(10). In vitro, the induction of a pro-oxidant state by ascorbate
and a subsequent reduction in mitochondrial membrane poten-
tial are involved in a caspase-8-independent apoptotic pathway
of B16F10 melanoma cells (11). Further, oral ascorbate supple-
mentation modulates B16FO melanoma growth, metastasis, and
inflammatory cytokine secretion as well as enhanced encapsu-
lation of tumors in scorbutic (l-gulono-gamma lactone oxidase
−/−) mice (12, 13).
www.frontiersin.org August 2014 | Volume 4 | Article 227 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Venturelli et al. Epigenetic impacts of ascorbate
In this respect, we recently demonstrated that patients afflicted
with metastatic melanoma (stage IV) have lower plasma ascorbate
levels compared to healthy controls and that polychemotherapy or
immunotherapy further decreases plasma ascorbate levels in stage
IV melanoma patients (14). However, the ascorbate concentra-
tion required for cytotoxicity in cancer cells can only be achieved
via intravenous (i.v.) administration (15); up to 49 mM ascorbate
blood peak concentrations are thus achievable by administration
of 70 g/m2 (16). Yet, in recent phase I clinical trials, ascorbate failed
to demonstrate a significant anticancer activity (16–19), although
it enhanced chemosensitivity of ovarian cancer cells and reduced
toxicity of chemotherapy (20). This obvious discrepancy between
impressive anticancer efficacy in various pre-clinical models and
lack of a reproducible anticancer activity in cancer patients clearly
demonstrates that crucial (co-)factors executing the anticancer
efficacy and an appropriate clinical treatment regimen remain to
be deciphered. Due to the broad concentration range of ascorbate
in humans and its numerous biochemical functions and effects,
which seem to differ in somatic and malignantly transformed
human cells (1), further research is needed for the understand-
ing of the precise cytotoxic molecular impacts of ascorbate in
cancer cells.
Many naturally occurring compounds and nutrients exert ben-
eficial anticancer effects (e.g., suppression of tumor growth or
induction of apoptosis), some of which are linked to modulation
of epigenetic mechanisms (21–23). In general, epigenetic mod-
ifications influence gene expression without altering the DNA
sequence and are therefore potentially reversible. Several epige-
netic changes were distinguished, including histone acetylation
and DNA methylation, and are currently investigated as potential
targets for anticancer therapy (24). Both of the latter regulate the
expression of microRNAs (miRNAs) and at the same time, are in
part controlled by miRNAs via a regulatory circuit (25, 26). miR-
NAs correlate with clinical outcome in cancer patients in clinical
studies (27). To test the possible relation between the expression of
any given miRNA and the clinical outcome of cancer patients, the
free online MIRUMIR tool, which performs survival analyses and
draws Kaplan–Meier plots for any miRNA across several available
data sets, was recently established (28).
In the present study, we provide novel evidence that in human
metastatic melanoma cells only pharmacological doses of ascor-
bate induce substantial epigenetic changes. For 8 mM ascorbate,
we detected a moderate inhibition of cellular histone deacety-
lase (HDAC) enzymes and a prominent DNA methyltransferase
(DNMT) inhibition. Only pharmacological doses of ascorbate
seemed to alter the miRNA expression profile by up-regulating
32 miRNAs mainly involved in tumor suppression and drug resis-
tance, as demonstrated by preliminary miRNA chip expression
analyses. Together, our results suggest that high doses of ascor-
bate only achievable in patients by i.v. administration might have
epigenetic impacts on melanoma cells that might be beneficial
in combination with classical or novel therapeutic anticancer
approaches.
MATERIALS AND METHODS
CELL LINES AND CHEMICALS
Metastatic melanoma cell lines [MeWo: derived from a lymph
node metastasis of a 78 years Caucasian donor; mutation status:
BRAF wild-type, NRAS wild-type (29), BLM: subline of BRO
melanoma cells isolated from lung metastases after subcuta-
neous inoculation of nude mice with BRO cells; mutation sta-
tus: BRAF wild-type, NRAS mutated (30)] were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS), 1% penicillin and streptomycin, and 1% l-glutamine. All
cell culture experiments were performed at 37°C and 5% CO2.
The following chemical was used: injectable vitamin C solution
(Pascorbin®, 150 mg ascorbate/1 ml injection solution, pH 7.0;
Pascoe pharmazeutische Praeparate GmbH, Giessen, Germany).
CELL-CYCLE ANALYSIS
BLM cells were incubated with ascorbate at 8 mM. After 0–24 h
(in 2 h intervals) the cells (1× 106) were harvested, washed with
cold PBS, fixed with 75% ethanol, and incubated at 4°C for at
least 1 h. Cells were then centrifuged and washed twice in cold
PBS. Intracellular DNA was labeled with propidium iodide solu-
tion [propidium iodide 40 mg/ml (Sigma) and RNase 100 mg/ml
(Thermo Scientific) in PBS] and incubated at 4°C for 30 min in the
dark. Cell cycle was analyzed using flow cytometry and FACSDiva
software (BD Biosciences, Heidelberg, Germany).
IN SILICO (DOCKING-) ANALYSIS OF HISTONE DEACETYLASE
INHIBITION
Ligand preparation
For this study, docking was performed into human HDACs 2,
4, 7, and 8 with trichostatin A (TSA) and the two major res-
onance structures of ascorbic acid (Figure 1). All ligands were
prepared using the molecular operation environment (MOE, ver-
sion 2007.09, Chemical Computing Group, Inc., Montreal, QC,
Canada). 3D representations of the ligands were obtained by
energy minimization (Rebuild3D function with preservation of
existing chiral centers) using MM94x force field and a Born Solva-
tion model without cutoff constraints. All other parameters were
left at default.
Protein preparation
Crystal structures of HDAC2 (PDB code: 3max), HDAC4 (PDB
code: 2vqm), HDAC7 (PDB code: 3c10), and HDAC8 (PDB code:
1t64) were retrieved from the protein data bank1 (PDB) and loaded
into MOE. The Protonate3D functionality was applied to assign
the correct ionization state and geometries to the protein atoms
and to add hydrogen atoms (31). For the final docking, water
molecules were discarded.
Docking
Docking was performed using GOLD (version 4.1.2, The Cam-
bridge Crystallographic Data Centre, Cambridge, UK). No addi-
tional protein preparation was applied. Binding sites were defined
by all residues within 5 Å distance from the corresponding ligands
in the crystal structure. Docking was performed using GoldScore
as scoring function. All other parameters were left at default.
Docking poses were analyzed in MOE. To optimize the ligand–
receptor interactions energy minimizations were applied using
MM94x force field and a Born Solvation model without cutoff
constraints.
1http://www.ebi.ac.uk/pdbe/
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FIGURE 1 | Ligands used for docking into the crystal structures of
HDAC-2, -4, -7, and -8.
HDAC-INHIBITOR SCREENING ASSAY
Determination of a possible HDAC-inhibitor activity of ascorbate
was done by using the HDAC assay kit (Active Motif, Rixensart,
Belgium). Ascorbate was diluted in assay buffer to the final con-
centrations of 5, 10, 20, 50, 100, 200µM, and 8 mM. Assay was
performed according to manufacturer’s protocol. Briefly, ascor-
bate was incubated with HeLa nuclear extract as a source of human
HDACs for 2 h at 37°C and the developing time was set to 10 min.
Each experiment was performed in triplicates and repeated three
times.
HDAC-INHIBITOR PROFILING ASSAY
The HDAC profiling assay was performed on basis of fluoro-
metric measurement by Scottish Biomedical (Scottish Biomed-
ical, Glasgow, UK). The percentage inhibition values of 50µM
and 8 mM ascorbate against human HDAC1, HDAC2, HDAC3,
HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10,
and HDAC11 was determined. Both concentrations of ascorbate
were tested in two experiments, each in duplicates. TSA is used
as a standard inhibitor by Scottish Biomedical for this assay and
was deployed according to the information of the manufacturer in
the following concentrations; HDAC1, HDAC2, HDAC3, HDAC6,
HDAC10, and HDAC11 were tested at 10 nM TSA, HDAC8 at
100 nM and HDAC4, HDAC5, HDAC7, and HDAC9 were tested
at 10µM TSA.
MEASUREMENT OF DNA METHYLTRANSFERASE ACTIVITY
Nuclear extracts were prepared from BLM and MeWo melanoma
cells (in triplicates) 12 h after 1 h treatment with ascorbate
(untreated, 200µM and 8 mM) by using the Nuclear Extract
Kit (Active Motif) according to the procedure described by the
manufacturer. DNMT activity was analyzed in the nuclear extracts
with the DNMT activity/inhibition assay (Active Motif) according
to the procedure described by the manufacturer.
miRNA EXPRESSION ANALYSIS
microRNA was isolated from BLM cells using the miRNeasy kit
(Qiagen, Hilden, Germany) according to the procedure described
by the manufacturer. miRNA expression analysis was performed
on BLM melanoma cells (five groups: untreated; 200µM, 8 mM
ascorbate treated, 4 and 12 h after the 1 h treatment, all in tripli-
cates) using the human miRNA Microarray Release 14.0, 8x15K
(Agilent, Waldbronn, Germany) based on Sanger miRbase (release
14.0). Two hundred nanograms of RNA were used per sam-
ple. The miRNA expression analysis was kindly performed at
the Genomic Core Facility of the European Molecular Biol-
ogy Laboratory (EMBL, Heidelberg, Germany) according to the
supplier’s instructions. Evaluation of raw data generated at the
Genomic Core Facility of the EMBL was performed as described
previously (32).
MIRUMIR miRNA ANALYSIS
Five highly up-regulated miRNA 12 h after 8 mM ascorbate treat-
ment (miR-596, miR-630, miR-490, miR-375, and miR-708) were
analyzed using the free online MIRUMIR database (28), which is
incorporated into BioProfiling.de, an analytical portal for high-
throughput cell biology2. The MIRUMIR database draws Kaplan–
Meier plots for the submitted miRNAs after an implemented
statistical procedure to account for multiple testing; P-values are
generated automatically.
STATISTICAL ANALYSIS
Statistical analysis was performed with One-way ANOVA Dun-
nett’s multiple comparison test using GraphPad Prism version
4.00 (GraphPad Software, San Diego, CA, USA). According to
One-way ANOVA Dunnett’s multiple comparison test, all ascor-
bate treatment groups were compared vs. vehicle/control. All
values of P > 0.05 were defined as statistically not significant.
The miRNA chip array was analyzed as described previously in
detail (32).
RESULTS
PHARMACOLOGICAL ASCORBATE INDUCES APOPTOSIS IN HUMAN
METASTATIC BLMMELANOMA CELLS IN A TIME-DEPENDENTMANNER
As shown previously (5), pharmacological doses of ascorbate in
the low millimolar-range induce cell death in human cancer cells.
However, since in the latter publication we only performed end-
point analyses 24 h after incubation of the cells with ascorbate,
for the current project we exposed BLM cells to pharmacological
8 mM ascorbate for 1 h, and the cells were ethanol-fixed every 2 h
for 24 h to closely monitor cell-cycle alterations at 2 h intervals over
24 h. The cell cycle was analyzed with FACS after staining of the
cells with propidium iodide. We observed that the G2/M fraction
of cells initially steadily increased starting at 2 h after ascorbate
exposure, while 12 h post-treatment a subsequent increase of the
2http://www.bioprofiling.de/MIRUMIR
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sub-G1 fraction of DNA fragmented cells was evident (indica-
tive for apoptotic cells). At 20 h post-treatment, the cell cycle was
already completely shifted toward the sub-G1 fraction (Figure 2).
At 12 h post ascorbate exposure only a small percentage of the
BLM cells were shifted toward the sub-G1 fraction of cells. There-
fore, the 12 h time point after ascorbate exposure was chosen for
the following experiments.
PHARMACOLOGICAL ASCORBATE MODERATELY INHIBITS HISTONE
DEACETYLASES
Epigenetic modifications such as histone acetylation or DNA
methylation play an important role in cancer development and
progression (24). Whether ascorbate has epigenetic effects on can-
cer cells has not been investigated yet. However, since reactive
oxygen species (ROS) induce hypermethylation of the E-cadherin
promoter regions in hepatoma cells (33), we hypothesized that
ascorbate, a pro-oxidative radical-inducing drug in pharmacolog-
ical concentrations (2, 5), might bear similar epigenetic effects on
melanoma cells. To verify our hypothesis, we therefore analyzed
two major epigenetic mechanisms, inhibition of DNMTs and
HDACs.
First we analyzed, if ascorbate possessed an HDAC-inhibitory
activity. To this end, an in silico docking analysis was performed.
The in silico analysis revealed that ascorbate was able to penetrate
into the binding pocket of class I and II HDACs and to inter-
act with the zinc ion, two issues that are important for HDAC
inhibitors (Figures 3A,B). Calculated GoldScores representing
the binding affinity, supported these first data, leading us to the
assumption that ascorbate, in a given setup, could be a similar
strong binding partner to the binding pockets as the well-known
HDAC-inhibitor TSA (Figure 3C) (22). Due to the positive results
obtained by the docking experiments, we next performed a cell free
HDAC-inhibitor assay. In this assay, nuclear extract of the well-
characterized human HeLa cell line was used as HDAC enzyme
source. The results showed that in contrast to the in silico docking
data, in vitro only a marginal inhibitory activity of ascorbate on
FIGURE 2 | Pharmacological ascorbate induces apoptosis in human
metastatic BLM melanoma cells in a time-dependent manner. BLM cells
were treated with 8 mM ascorbate for 1 h. Cells were ethanol-fixed every 2 h
for 24 h, stained with propidium iodide, and cell cycle was analyzed with
FACS. Depicted are the FACS plots for the untreated control cells and for 2, 4,
6, 8, 12, 16, 20, and 24 h after ascorbate exposure. The G2/M fraction of cells
steadily increased from 2 to 8 h, while 12 h post-treatment a prominent
increase of the sub-G1 fraction of DNA fragmented cells started (indicative for
apoptosis induction). At 20 h post-treatment, the cell cycle was already
completely shifted toward the sub-G1 fraction. Gray colored graphs indicate
the control cells; black colored graphs (2–8 h) the initial shift into G2/M phase;
red colored graphs (12–24 h) the subsequent shift into sub-G1 fraction.
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FIGURE 3 | In silico docking analysis of ascorbate and HDACs.
(A) In silico docking analyses of ascorbate and HDAC2, HDAC4, HDAC7,
and HDAC8. Trichostatin A (TSA) served as positive control. The analysis
demonstrates the fitting of ascorbate into each HDAC binding pocket and
the ability to interact with the HDAC-derived zinc ion (turquoise sphere)
of the catalytic center. (B) 2D depiction of ligand is shown along with
interacting amino acids. Green circles represent greasy, purple circles
polar, red circles acidic, and blue circles basic amino acids. HDAC
contacts are depicted by a blue half moon around the amino acids. Blue
arrows represent backbone acceptors, green ones depict side chain
acceptors and side chain donors. Green benzoyl rings with a “+”
describe an arene–cation binding, two benzoyl rings an arene–arene
binding. Areas with a blue background are exposed to the ligand. The
purple dotted lines represent metal contact. (C) Docking analysis of
ascorbate in the individual HDAC binding pockets were performed using
GOLD software (version 4.1.2) and MOE.
HDACs could be detected (Figure 4A). The latter data could be
verified by a profiling of all known HDAC enzymes of class I, II,
and IV. As before, TSA was used as reference HDAC inhibitor
in this experimental setting. In line with the HDAC-inhibitor
assay above, neither the physiological 50µM nor the pharma-
cologic 8 mM ascorbate showed a significant inhibition of the 11
conserved human HDACs tested when compared to the potent
inhibition mediated by TSA (Figure 4B).
PHARMACOLOGICAL ASCORBATE INHIBITS
DNA METHYLTRANSFERASES
Due to the negative results of the HDAC inhibition assays, we next
investigated if ascorbate had a DNMT inhibitory activity in the
human metastatic MeWo and BLM melanoma cells. Twelve hours
after treatment of the respective melanoma cells with either phys-
iological 200µM or pharmacological 8 mM ascorbate for 1 h, a
nuclear extract was prepared and the amount of methylated DNA
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FIGURE 4 | Ascorbate does not act as histone deacytelase inhibitor
(HDACi). (A) Overall HDAC inhibition in cellular extracts of the human cell
line HeLa by increasing concentrations of ascorbate (5–8000µM). As
reference inhibitor 100µM suberoylanilide hydroxamic acid (SAHA) was
used. Every concentration was tested three times in triplicates. (B) Specific
fluorometric profiling assay using recombinant human HDACs of classes I,
II, and IV. Specific inhibition values were generated for the treatment with
50µM and 8 mM ascorbate. Inhibition values for every HDAC were yielded
by two experiments, each performed in duplicates. Shown are mean±SD.
One-way ANOVA Dunnett’s multiple comparison test, n.s. indicates not
significant.
was measured. The experiments showed that the physiological
concentration of ascorbate (200µM) increased the DNMT activity
in a moderate fashion in both cell lines. Interestingly, the phar-
macological concentration of 8 mM ascorbate clearly inhibited
DNMTs in both cell lines by up to 40% (Figure 5).
PHARMACOLOGICAL ASCORBATE STRONGLY MODIFIES miRNA
EXPRESSION
The novel classification of pharmacological ascorbate as DNMT
inhibitor rose the question if the inhibition of DNMTs within
the melanoma cells subsequently had an impact on the cel-
lular miRNA expression profile. To answer this question, we
performed miRNA expression chip analysis. The investigation
revealed that the expression of 151 miRNAs was significantly
altered when comparing ascorbate treatment for 1 h at 8 mM
with treatment at 200µM (Figure 6). The IC50 of ascorbate is
in the low millimolar range in melanoma cells (5). Since in this
FIGURE 5 | Ascorbate inhibits DNA methyltransferase (DNMT) activity
in melanoma cells. Global DNMT activity was determined in nuclear
extracts of MeWo and BLM cells 12 h after 1 h treatment with 200µM or
8 mM ascorbate. Treatment with 200µM ascorbate increases DNMT
activity in MeWo and BLM cells by 4 and 18%, respectively, and 8 mM
ascorbate inhibits DNMT activity by 43 and 35%, respectively.
study, we mainly investigated the role of epigenetic mechanisms
accompanying ascorbate-induced cytotoxicity, we did not focus
on miRNA expression changes induced by physiological ascor-
bate (200µM), which bears no cytotoxic effect on melanoma
cells. Comparing the impact of the pharmacological dose of
ascorbate (8 mM) with the impact of ascorbate at the maxi-
mum physiological plasma condition of 200µM, after 12 h a
significant up-regulation of 32 miRNAs (4- to 38-fold) could
be stated. Interestingly, 14 of these miRNAs (miR-596, miR-630,
miR-422a, miR-490-5p, miR-375, miR-708, miR-345, miR-125b-
2, miR-516a-3p, miR-135a, miR-1228, miR-1915, miR-134, and
miR-663) have established roles in tumor suppression and drug
resistance, while 5 miRNAs (miR-630, miR-375, miR-345, miR-
1228, and miR-134) are known to inhibit epithelial–mesenchymal
transition and invasion in cancer cells. Eleven of the up-regulated
miRNAs (miR-887, miR-583, miR-662, miR-1973, miR-718, miR-
1268, miR-2117, miR-614, miR-617, miR-1972, and miR-1181)
have no reported functions in cancer cells yet. A detailed list
of the 32 up-regulated miRNAs, their reported expression pro-
file in cancer, functions and predicted RNA-targets are given in
Table 1. To further analyze a possible clinical significance of the
up-regulated miRNA upon ascorbate administration, we screened
the free MIRUMIR online database (28), which tests any given
miRNA as biomarker to predict survival in available clinical data
sets that cover more than 800 cancer patients. We were able to
find a strong correlation of high expression of miR-596, miR-630,
miR-490, miR-375, and miR-708 with overall long-term survival in
breast cancer or nasopharyngeal carcinoma patients when com-
pared to low expression of the respective miRNA in the same
cohorts of patients. The Kaplan–Meier plots as depicted in Figure 7
were automatically generated by MIUMIR upon submission of the
respective miRNAs (miR-596, miR-630, miR-490, miR-375, and
miR-708).
DISCUSSION
Cutaneous melanoma is an aggressive malignancy with increasing
incidence. Up to now curative therapies for stage IV patients,
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FIGURE 6 | Ascorbate alters the expression of miRNA in melanoma
cells. A miRNA expression chip analysis was performed on human
(Continued)
FIGURE 6 | Continued
metastatic BLM melanoma cells (5 groups: untreated, 200µM ascorbate,
8 mM ascorbate, both 4 and 12 h after ascorbate exposure; all in triplicates)
using the human miRNA Microarray Release 14.0, 8x15K (Agilent
Technologies) based on Sanger miRbase (release 14.0). A total of 151
miRNAs were differentially expressed in response to ascorbate. Incubation
of BLM cells with 8 mM ascorbate for 1 h up-regulated 32 miRNAs (4- to
38-fold) involved in tumor suppression and drug resistance compared to
physiological (200µM) ascorbate after 12 h.
which have an overall survival of 9–14 months,are lacking (81–83).
Therefore, in spite of the recently approved targeted drugs (BRAF-
or MEK-inhibitors) or available immunotherapies (anti-CTLA-
4- or anti-PD1-antibodies) novel therapeutic strategies are still
urgently needed. Numerous alternative treatment approaches are
therefore currently investigated in the context of cancer therapy.
A highly controversial and also emotionally discussed approach,
the application of ascorbate in pharmacological doses, was first
proposed and described by Pauling and Cameron in the 1970s (84,
85). Although their original hypothesis concerning the mode of
action was incorrect (encapsulation of tumors by collagen induc-
tion), in the mean time it became evident that the anticancer effects
of ascorbate are principally mediated by induction of radicals (1,
4). Furthermore, the crucial need for i.v. administration instead of
oral supplementation to assure a sufficient, cytotoxic drug concen-
tration has widely been acknowledged (86). This partly explains
why the clinical observations of Pauling and Cameron could not
be reproduced in clinical trials conducted in the 1980s. We recently
observed functional effects of ascorbate on survival of melanoma
cells (5). In the latter paper, we showed the cytotoxic effect of
ascorbate on all 60 cancer cell lines of the NCI60 panel of cancer
cells, which includes 9 human melanoma cell lines. The IC50 of
ascorbate was 3.1 mM for all melanoma cell lines (0.2–8.5 mM);
the overall IC50 of all 60 cancer cell lines was 4.5 mM. 8 mM ascor-
bate generated a high amount of intracellular peroxide radicals in
LOX-IMVI melanoma cells leading to an increased percentage of
sub-G1 (apoptotic) cells determined by FACS. In the melanoma
cell lines,ascorbate treatment at the individual IC50 concentrations
decreased GLUT-1 expression (pro-survival HIF-1α downstream
target). In line, in the present paper, we observed a similar time-
dependent prominent increase of BLM melanoma cells in the
sub-G1 fraction, beginning at 12 h after incubation of the cells
with 8 mM ascorbate.
Surprisingly, despite the abundance of scientific reports eluci-
dating the mechanistic background of pharmacological ascorbate-
induced cancer cell cytotoxicity, independent of the cellular muta-
tion status, the successful transfer into the clinics has failed so far.
The most likely explanations for this discrepancy are (i) the obser-
vation of induced ascorbate resistance by exogenous factors such
as hypoxia present in metastatic tissue of cancer patients, which
clinically has not been taken into consideration yet (5), and (ii)
the existence of possible additional endogenous mechanistic fea-
tures driven by ascorbate. Such additional effects might severely
influence its cytotoxic efficacy for the treatment of cancer.
In the last few years, increasing evidence demonstrated that nat-
ural products and edibles harbor epigenetic activities, which might
be beneficial for cancer therapy (24, 87). Epigenetic alterations that
induce multiple changes in gene expression profiles are substantial
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Table 1 | miRNA expression profile of BLM melanoma cells after ascorbate treatment.
miRNA Up-regulation
(2× log2)
Expression in cancer Function Predicted targets (mir SVR scorea) Reference
hsa-miR-596 5.26 Urothelial carcinoma 174 UC and 33 UC cells
Ependymoma
Hepatocellular carcinoma tissue
Oral squamous cell carcinoma
Candidate tumor suppressor gene region
Expression correlates with survival
Expression correlates with survival
Tumor suppressor in vivo
ABCB5 (multidrug resistance exporter,
over-expressed in melanoma)
(34)
(35)
(36)
(37)
hsa-miR-887 5.14 N/A PDK1 (Akt pathway), FN1 (c-MET/HGF-pathway),
MAP3K1 (apoptosis)
hsa-miR-630 4.3 Non-small cell lung cancer A549 cells Modulates mitochondrial/post-mitochondrial steps
of the intrinsic pathway of apoptosis; blocks early
manifestations of the DNA damage response
IGF2BP3 (proliferation), CDK1 (interacts with
FOXO1a, tumor suppression), FANCI (DNA
repair), EP300 (MITF-pathway), Wnt/b-catenin,
SLUG
(38)
Lung cancer Suppresses SLUG in vivo and thus epithelial
mesenchymal transition in an integrin
α(1)β(1)/FAK/ERK/SP1 pathway-dependent manner
(39)
Pancreas cancer cells Induces apoptosis in pancreatic cancer cells by
targeting IGF-1R
(40)
hsa-miR-422a 4.29 Osteosarcoma tissue and cells Up-regulation predicts tumor sensitivity to
ifosfamide
RBX1 (proteasomal degradation) (41)
hsa-miR-583 3.97 N/A KIT, RCC1 (oncogenes)
hsa-miR-490-5p 3.91 Bladder cancer tissue Down-regulated in bladder cancer PI3K (mTOR/AKT pathway), NGR1 (invasiveness),
IL7 (activates JAK/STAT5), PTPRD (tumor
suppression)
(42)
hsa-miR-375 3.65 Pancreatic ductal adeno-carcinoma tissue
and cells
Down-regulated in pancreas cancer (43)
Gastric cancer tissue and cells Tumor suppressor regulating gastric cancer cell
proliferation
(44, 45)
Hepatocellular carcinoma tissue Inhibits proliferation and invasion of HCC cells via
suppression of endogenous YAP oncogene protein
level
(46)
Head and neck squamous cell carcinoma
tissue and cells
Down-regulated in head and neck squamous cell
cancer
(47)
Esophagus squamous cell and
adeno-carcinoma tissues
Down-regulation is associated with worse
prognosis
(48)
Cervical cancer cell lines Tumor suppressor in cervical carcinogenesis (49, 50)
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miRNA Up-regulation
(2× log2)
Expression in cancer Function Predicted targets (mir SVR scorea) Reference
hsa-miR-662 3.59 N/A
hsa-miR-708 3.48 Colon carcinoma tissue and cells Expressed in colon carcinoma, regulates
oncogenetic (MAPK, PI3K) pathways
IKBKB (NFκB activation), SPARC (invasiveness,
EMT induction), ANXA1 (migration)
(51)
Renal cell carcinoma Tumor suppressor in renal cell carcinoma in vivo (52)
Prostate cancer Decreases tumorigenicity of CD44(+) prostate
cancer-initiating cells in vitro and in vivo
(53)
Glioblastoma Tumor suppressor in human glioblastoma cells (54)
hsa-miR-654-5p 3.39 Prostate cancer cells Regulates expression of androgen receptor AKT (proliferation), notch-1 (oncogene in
melanoma)
(55)
hsa-miR-629 3.38 Breast, colon, liver, lung, lymphoma, ovary,
prostate, testis cancer tissue
Up-regulated in various cancers ZBTB16 (melanoma progression), PPARG
(apoptosis induction)
(56, 57)
hsa-miR-564 3.28 Chronic myeloid leukemia cells Down-regulated in chronic myeloid leukemia cells (58)
hsa-miR-1973 3.08 N/A SHC4 (RAS activation)
hsa-miR-718 2.97 N/A
hsa-miR-1268 2.84 N/A
hsa-miR-345 2.82 Breast adeno-carcinoma MCF-7 cells Targets the human multidrug
resistance-associated protein 1
(59)
Colon cancer cells Suppresses colon cancer cell proliferation and
invasiveness
BCL2-associated athanogene 3 (BAG3) (60)
hsa-miR-125b-2 2.8 Large cell lung carcinoma Calu-6 cells Putative tumor suppressor residing in the
commonly deleted 21q21 region
TNF (proinflammatory cytokine) (61)
hsa-miR-2117 2.65 N/A SPP1 (invasiveness, EMT, over-expressed in
melanoma)
hsa-miR-614 2.61 N/A
hsa-miR-516a-3p 2.56 Ovarian cancer cells Decreases cell proliferation via decrease of
kallikrein-related peptidases (KLKs)
ABCB5 (multidrug resistance exporter,
over-expressed in melanoma)
(62)
hsa-miR-339-3p 2.47 B-cell precursor acute lymphoblastic
leukemia cells
Over-expressed in pre-B-ALL patients (63)
(Continued)
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miRNA Up-regulation
(2× log2)
Expression in cancer Function Predicted targets (mir SVR scorea) Reference
hsa-miR-135a 2.45 Non-small lung carcinoma cells Involved in paclitaxel resistance MS4A1 (B-cell activation), MCL1 (64)
Sensitizes A549 lung cancer cells for
cisplatin-induced apoptosis
(65)
hsa-miR-99b 2.44 Primary melanoma tissues Increased expression in melanomas of older
patients
(66)
Esophageal cancer Up-regulated in esophageal cancer (67)
hsa-miR-1225-5p 2.38 Prostate cancer cells Androgen-regulated in prostate cancer cells (68)
hsa-miR-617 2.33 N/A
hsa-miR-1228 2.24 Malignant mesothelioma tissue Up-regulated in malignant mesothelioma CK2A2 (69)
Gastric cancer Suppressed gastric cancer formation in vivo,
suppresses epithelial mesenchymal transition
(70)
hsa-miR-1915 2.22 Human embryonal stem cells Inhibits notch-1 in silico BCL2 (71)
Colon carcinoma cells Sensitizes HCT116 colon cancer cells to anticancer
drugs
(72)
hsa-miR-1972 2.22 N/A
hsa-miR-134 2.15 Small cell lung cancer NCI-H69 and
NCI-H69AR cells
Reduces sensitivity to cisplatin, etoposide and
doxorubicin by induction of G1 arrest
FOXM1, Nanog, KRAS (73)
Non-small cell lung cancer cells Inhibits epithelial mesenchymal transition (74)
Glioblastoma Down-regulated in glioblastoma (75)
Hepatocellular carcinoma Suppresses HCC in vivo by down-regulation of
KRAS
(76)
hsa-miR-1246 2.13 Malignant mammary epithelial cells Released into blood, milk, and ductal fluids,
possible biomarker
(77)
hsa-miR-1181 2.06 N/A
hsa-miR-663 2.05 Colon cancer SW480 cells Resveratrol-induced tumor suppressor targeting
TGFb1 transcripts
(78)
Gastric cancer BGC823 and SNU5 cells Tumor suppressor in gastric cancer cells (79)
Melanoma tissue samples Up-regulated in melanoma (80)
ahttp://www.microrna.org/microrna/home.do
List of differentially expressed miRNAs 12h after exposure of BLM cells to 8mM ascorbate for 1 vs. 12 h after exposure to 200µM ascorbate for 1 h, up-regulation >2× log2.
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FIGURE 7 | High expression of miRNA up-regulated by ascorbate
in melanoma cells correlates with increased overall survival in
cancer patients. The MIRUMIR online database was screened to
detect an impact of the up-regulated miRNA (compare Figure 6) on
cancer patient survival. The depicted Kaplan–Meier plots are
automatically drawn by MIRUMIR upon submission of the respective
miRNAs. A significant correlation of high expression of miR-596,
miR-630, miR-490, miR-375, and miR-708 with overall long-term
survival in breast cancer (GEO dataset IDs: GSE37405 and GSE37405)
or nasopharyngeal carcinoma patients (GEO dataset ID: GSE36682)
was observed when compared to low expression of the respective
miRNA.
features of cancer (88–90). Several epigenetic mechanisms have
been described so far and the investigation of this complex molec-
ular machinery is ongoing. Two principal mechanisms that cause
a silencing of control genes and mediate tumor formation as well
as tumor progression are the modulation of HDACs and the regu-
lation of DNMTs. Therefore, in the present study, we investigated
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possible epigenetic impacts of ascorbate on melanoma cells to gain
a more profound understanding of this alternative therapeutic
approach widely used in complimentary medicine (91).
In particular, our in silico findings showed that ascorbate fits
into the catalytic pocket of human HDACs and interacts with the
zinc ion as well as other residues of the active site making it an inter-
esting candidate that could act as a histone deacytelase inhibitor
(HDACi). The obtained GoldScore values even assigned ascor-
bate to be a similar potent inhibitor as the well-known HDACi
TSA. To verify these results, different HDAC inhibition assays
were performed. However, neither the inhibition experiments with
nuclear extracts nor the extensive profiling study could prove that
ascorbate substantially inhibits classical human HDACs in vitro.
Our second attempt was to test, if ascorbate can inhibit DNMTs
within melanoma cells. Indeed, we could show that physiolog-
ical levels of ascorbate in the micromolar range have no or a
slightly activating activity on DNMTs, whereas pharmacological
levels of ascorbate in the millimolar-range (achievable in patients
via i.v.-administration) inhibit cellular DNMTs in melanoma cell
lines. Based on these results, we conclude that ascorbate bears a
novel DNMT inhibitory activity in high concentrations, but no
HDAC-inhibitory potential.
Due to the newfound epigenetic activity of pharmacological
ascorbate on DNMTs we next analyzed its impact on expres-
sion of miRNAs. The results of the chip analysis highlighted
that upon stimulation of melanoma cells with either physiolog-
ical or pharmacological ascorbate, a total of 151 miRNAs were
differentially regulated in comparison to the untreated cells. Most
interestingly, by comparing the melanoma cells incubated with the
maximum physiological dose of 200µM to cells pre-conditioned
with pharmacological 8 mM to specifically analyze the impact of
cytotoxicity-inducing drug concentrations, it became obvious that
the majority of the up-regulated miRNAs are known to be involved
in tumor suppression, cancer cell drug resistance, or inhibition of
migration and invasion through inhibition of epithelial mesenchy-
mal transition. The last-mentioned is a typical morphogenetic
feature in the developing embryo untimely reappearing in can-
cer cells in general and in melanoma cells, in particular, due to
their neural crest origin (92–94). Since the miRNAs found to be
up-regulated upon ascorbate stimulation in the chip analysis were
not validated by additional real-time PCR analyses, definite con-
clusions or a clear clinical significance cannot be drawn of the
rather preliminary results yet. However, the up-regulated expres-
sion of miRNA due to ascorbate in melanoma cells correlated
with an increased overall survival of breast cancer or nasopha-
ryngeal carcinoma patients of the MIRUMIR database (28) with
high expression of the respective miRNAs, therefore, suggest-
ing a possible beneficial clinical relevance of the specific miRNA
up-regulation by ascorbate. At this point, our results therefore
allow us to generate the hypothesis that pharmacological ascor-
bate might modify the miRNA signature of melanoma cells, which
subsequently might be beneficial for overall survival of melanoma
patients in analogy to the endogenous miRNA expression pro-
files of breast cancer and nasopharyngeal carcinoma patients with
either short- or long-term survival.
Considering the observed preliminary up-regulation of specific
miRNAs by ascorbate (possibly via its novel DNMT inhibitory
activity) governing a broad spectrum of tumor-suppressive
effects including apoptosis induction, antiproliferative activity,
and decrease of cancer cell invasion, this novel epigenetic signature
of ascorbate might open the door for the exploration of ascorbate
in combination with other classical or even epigenetically active
molecules for cancer therapy (90) and therefore warrants further
pre-clinical and clinical investigation.
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